Cholesterol crystal embolism: A recognizable cause of renal disease

被引:187
作者
Scolari, F
Tardanico, R
Zani, R
Pola, A
Viola, BF
Movilli, E
Maiorca, R
机构
[1] Spedali Civil Brescia, Div Nephrol, I-25125 Brescia, Italy
[2] Spedali Civil Brescia, Chair Nephrol, I-25125 Brescia, Italy
[3] Spedali Civil Brescia, Dept Pathol, I-25125 Brescia, Italy
[4] Spedali Civil Brescia, Chair Pathol, I-25125 Brescia, Italy
[5] Univ Brescia, I-25121 Brescia, Italy
关键词
atherosclerosis; cholesterol crystals; renal atheroembolic disease;
D O I
10.1053/ajkd.2000.19809
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cholesterol crystal embolism, sometimes separately designated atheroembolism, is an increasing and still underdiagnosed cause of renal dysfunction antemortem in elderly patients. Renal cholesterol crystal embolization, also known as atheroembolic renal disease, is caused by showers of cholesterol crystals from an atherosclerotic aorta that occlude small renal arteries. Although cholesterol crystal embolization can occur spontaneously, it is increasingly recognized as an iatrogenic complication from an invasive vascular procedure, such as manipulation of the aorta during angiography or vascular surgery, and after anticoagulant and fibrinolytic therapy. Cholesterol crystal embolism may give rise to different degrees of renal impairment. Some patients show only a moderate loss of renal function; in others, severe renal failure requiring dialysis ensues. An acute scenario with abrupt and sudden onset of renal failure may be observed. More frequently, a progressive loss of renal function occurs over weeks. A third clinical form of renal atheroemboli has been described, presenting as chronic, stable, and asymptomatic renal insufficiency. The renal outcome may be variable; some patients deteriorate or remain on dialysis, some improve, and some remain with chronic renal impairment. In addition to the kidneys, atheroembolization may involve the skin, gastrointestinal system, and central nervous system. Renal atheroembolic disease is a difficult and controversial diagnosis for the protean extrarenal manifestations of the disease. In the past, the diagnosis was often made postmortem. However, in the last decade, awareness of atheroembolic renal disease has improved, enabling us to make a correct premortem diagnosis in a number of patients. Correct diagnosis requires the clinician to be alert to the possibility. The typical patient is a white man aged older than 60 years with a baseline history of hypertension, smoking, and arterial disease. The presence of a classic triad characterized by a precipitating event, acute or subacute renal failure, and peripheral cholesterol crystal embolization strongly suggests the diagnosis. The confirmatory diagnosis can be made by means of biopsy of the target organs, including kidneys, skin, and the gastrointestinal system. Thus, Cinderella and her shoe now can be well matched during life. Patients with renal atheroemboli have a dismal outlook. A specific treatment is lacking. However, it is an important diagnosis to make because it may save the patient from inappropriate treatment. Finally, recent data suggest that an aggressive therapeutic approach with patient-tailored supportive measures may be associated with a favorable clinical outcome. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:1089 / 1109
页数:21
相关论文
共 75 条
[1]  
[Anonymous], 1986, LANCET, V1, P397
[2]   Mechanisms of plaque rupture: mechanical and biologic interactions [J].
Arroyo, LH ;
Lee, RT .
CARDIOVASCULAR RESEARCH, 1999, 41 (02) :369-375
[3]   ATHEROEMBOLIC INVOLVEMENT OF RENAL-ALLOGRAFTS [J].
AUJLA, ND ;
GREENBERG, A ;
BANNER, BF ;
JOHNSTON, JR ;
TZAKIS, AG .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1989, 13 (04) :329-332
[4]   CHOLESTEROL EMBOLISM AS A CAUSE OF TRANSIENT ISCHEMIC ATTACKS AND CEREBRAL INFARCTION [J].
BEAL, MF ;
WILLIAMS, RS ;
RICHARDSON, EP ;
FISHER, CM .
NEUROLOGY, 1981, 31 (07) :860-865
[5]   Supportive treatment improves survival in multivisceral cholesterol crystal embolism [J].
Belenfant, X ;
Meyrier, A ;
Jacquot, C .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (05) :840-850
[6]  
BELLAMY COC, 1994, NEPHROL DIAL TRANSPL, V9, P182
[7]   Cholesterol embolisation after thrombolytic therapy [J].
Blankenship, JC .
DRUG SAFETY, 1996, 14 (02) :78-84
[8]   PROSPECTIVE ASSESSMENT OF CHOLESTEROL EMBOLIZATION IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION TREATED WITH THROMBOLYTIC VS CONSERVATIVE THERAPY [J].
BLANKENSHIP, JC ;
BUTLER, M ;
GARBES, A .
CHEST, 1995, 107 (03) :662-668
[9]  
Bolander JE, 1996, J AM SOC NEPHROL, V7, P18
[10]   REVERSAL OF GANGRENOUS LESIONS IN THE BLUE TOE SYNDROME WITH LOVASTATIN - A CASE-REPORT [J].
CABILI, S ;
HOCHMAN, I ;
GOOR, Y .
ANGIOLOGY, 1993, 44 (10) :821-825